Drilldown: Medicines

Other values:

Search

None (24) · Adderall, Adderall XR, Mydayis (1) · Anafranil (1) · Aurorix (1) · Captagon (1) · Cymbalta, Drizalma Sprinkle, Irenka, Yentreve (1) · Desoxyn (1) · Dexedrine (1) · DXM (1) · DXO (1) · Edronax (1) · Fetzima (1) · Ludiomil (1) · Marplan (1) · Nardil (1) · Norpramin (1) · Parnate (1) · Savella (1) · Serzone (1) · Spravato (1) · Stablon (1) · Surmontil (1) · Tofranil (1) · Valdoxan (1) · Vivactil (1) · Zoloft (1)

Research material · Classic Psychedelic · Stimulant · Opioid · Sedative-Hypnotic · Phenethylamine · Tryptamine · Benzodiazepine · Botanical · [[:Category:Antihypertensives|Antihypertensive]] · Dissociative · Anticonvulsant · Antidepressant · Plant Medicine · Analgesic · Antipsychotic · Antiparkinsonian · Empathogen · Neuroleptic · Cathinone

Other values:

Search

None (1) · Active metabolite of DXM; NMDA antagonist (1) · Contains salvinorin A (1) · Irreversible non-selective MAO inhibitor (3) · Kappa-opioid agonist; NMDA antagonist; SERT/DAT/NET inhibitor (1) · Kappa-opioid receptor agonist (1) · Melatonin receptor agonist; 5-HT2C antagonist (1) · Monoamine releasing agent (6) · Monoamine releasing agent, TAAR1 agonism, VMAT2 substrate, DAT/NET reverse transport (1) · Monoamine releasing agent; serotonergic at higher doses (1) · Mu-opioid agonist; modulates glutamate AMPA receptors (1) · NMDA antagonist (3) · NMDA antagonist; endogenous opioid releaser (1) · NMDA antagonist; fluorinated ketamine analogue (1) · NMDA antagonist; kappa-opioid agonist (1) · NMDA antagonist; ketamine analogue (1) · NMDA antagonist; more stimulating than PCP (1) · NMDA antagonist; opioid agonist (1) · NMDA antagonist; potent opioid agonist (1) · NMDA antagonist; SERT inhibitor; sigma-1 agonist (1) · NMDA antagonist; sigma receptor agonist (2) · NMDA antagonist; sigma receptor agonist; dopaminergic (1) · NMDA antagonist; sigma-1 agonist; serotonin reuptake inhibitor (1) · Potent serotonin reuptake inhibitor; also NRI (1) · Prodrug of amphetamine + theophylline (1) · Reversible inhibitor of MAO-A (1) · Selective norepinephrine reuptake inhibitor (3) · Serotonin and norepinephrine reuptake inhibitor (3) · Serotonin reuptake inhibitor and 5-HT2A antagonist (1) · Serotonin–norepinephrine reuptake inhibition (balanced) (1) · Serotonin–norepinephrine reuptake inhibitor (2) · TAAR1 agonism, VMAT2 substrate, DAT/NET reverse transport, net release of dopamine and norepinephrine (1) · TrkB/BDNF'"`UNIQ--ref-00000084-QINU`"' '"`UNIQ--vote-00000085-QINU`"' (1) · Weak SRI; primarily H1/D2/alpha antagonist (1)

None (45) · Depression, anxiety, neuropathic pain, fibromyalgia, chronic musculoskeletal pain (1) · Treatment-resistant depression (TRD) in adults, as adjunct to oral antidepressant (FDA-approved March 2019). Depressive symptoms in adults with MDD with acute suicidal ideation or behavior (FDA-approved Aug 2020). (1) · '"`UNIQ--vote-000004B9-QINU`"', '"`UNIQ--vote-000004BA-QINU`"', '"`UNIQ--vote-000004BB-QINU`"' (1) · '"`UNIQ--vote-00000562-QINU`"', '"`UNIQ--vote-00000563-QINU`"', '"`UNIQ--vote-00000564-QINU`"', '"`UNIQ--vote-00000565-QINU`"', '"`UNIQ--vote-00000566-QINU`"' (1)

None (45) · 2.5 mg IR, 5 mg XR, or 12.5mg Mydayis (1) · 25 mg (1) · 5 mg PO (1) · Induction (TRD): 56 mg intranasal twice weekly × 4 weeks. Maintenance: 56-84 mg once weekly × 4 weeks, then 56-84 mg every 1-2 weeks. For acute suicidality: 84 mg twice weekly × 4 weeks. Administered under medical supervision in REMS-certified site. (1)

None (45) · 25 mg, 50 mg, 100 mg tablets; oral concentrate 20 mg/mL (1) · 28 mg/device (each dose uses 2 devices) (1) · Desoxyn 5 mg tabs (1) · IR tabs 5, 7.5, 10, 12.5, 15, 20, 30 mg; XR caps 5, 10, 15, 20, 25, 30 mg; Mydayis caps 12.5, 25, 37.5, 50 mg (1)

None (45) · 200 mg/d (1) · 25 mg/day (ADHD per Desoxyn label); 15 mg/day (obesity, short-term, per Desoxyn label) (1) · 84 mg per session (1) · XR = 40 or 60 mg/d; IR = 40 or 60 mg/d'"`UNIQ--ref-00000567-QINU`"' (1)

None (44) · Intranasal (under direct medical supervision) (1) · Oral (3) · Oral (prescribed) (1)

None (45) · Anxiolysis classically 3-4 weeks, continuing improvement to 8-12 weeks (1) · IR: 30–60 min; XR: 1–2 h to peak effect (1) · Mood: 2–4 weeks. Pain: often within 1–2 weeks. (1) · Within hours of first administration (1)

None (45) · Acute effect ~24 hours; cumulative effect builds with repeated dosing (1) · Chronic daily dosing (1) · IR 4–6 h; XR 10–12 h; Mydayis 14–16 h (1) · Long (1)

None (45) · D-amphetamine ~10 h; L-amphetamine ~13 h (adults) (1) · ~12 hours (1) · ~26 h (sertraline; range 13-45 h, longer in females); ~62-104 h (N-desmethylsertraline, weakly active) (1) · ~7-12 hours (1)

None (45) · Absolute bioavailability not precisely characterized; food modestly increases exposure (1) · ~48% intranasal (1) · ~50% (highly variable) (1) · ~75–90% (oral) (1)

None (44) · Avoid; may cause fetal harm (1) · Category C (2) · Category C (per Desoxyn label) (1) · Category C'"`UNIQ--ref-0000008F-QINU`"' (1)

None (44) · Rx, Schedule III (US). REMS program required. (1) · Rx-only (1) · Rx-only in US (1) · Schedule II (2)